Development of a novel targeted antibody fusion protein as a new generation cancer therapeutic-Rathin Das-06/30/2015 - 8:30am

Event Information
Event Topic: 
Development of a novel targeted antibody fusion protein as a new generation cancer therapeutic
Event Date: 
06/30/2015 - 8:30am
Event Location: 
Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA
Speaker Information
Event Speaker: 
Rathin Das
Event Speaker Title: 
Event Speaker Company: 
Synergys Biotherapeutics
Event Speaker Bio: 

Dr. Rathin Das is the Founding President and CEO of Synergys Biotherapeutics, Inc., an antibody therapeutics company based in Walnut Creek, CA. Before founding Synergys in 2009, he worked for Affitech AS of Oslo, Norway, an antibody therapeutics company, for 10 years. He served as the Senior Vice President of Corporate Development and Chief Business Officer as well as President of its US operation, Affitech USA, Inc.

Dr. Das has more than 30 years of experience in big pharma and biotech, including 15 years at Bayer Corporation in the US and Europe, and has published numerous articles in both peer-reviewed and trade journals. He holds both a PhD in Bioorganic Chemistry and an MBA, and has several years of experience in postdoctoral experience in cell and molecular biology at the University of Iowa, Iowa City, and the Cancer Research Center at MIT. Dr. Das also founded the Indiana Section of the Society of Industrial Microbiology, USA in 1986.

Event Details
Event Details: 

While tumor growth is supported by endothelial cell angiogenesis, research suggests that tumor vasculature may be assembled through the formation and lining of vascular channels by tumor cells themselves.This process is called “vasculogenic mimicry” (VM). VM may supplement angiogenesis and provide an additional mechanism for tumors to generate a nutrient supply; it has also been linked to tumor aggressiveness and metastasis.

Since therapeutic disruption of VM has been largely unexplored and many anti-angiogenic drugs in current use have little or no activity against VM, Synergys is developing a targeted antibody fusion protein that is an excellent anti-angiogenic and also demonstrates profound inhibition of VM and inhibition of tumor growth. Dr. Das will present Synergys’ recent research results.